The Weill Cornell Medicine Lymphoma Program has recently opened a new clinical trial for men and women with relapsed/refractory lymphoma. The study sponsor is PIQUR Therapeutics AG, and the principal investigator at Weill Cornell is Lisa Roth M.D. For more information about the study, please call Catherine Babaran, RN at 212-746-2651 or e-mail Catherine at cmb9017@med.cornell.edu.
Key Eligibility
- Men and women age 18 and older with histologically confirmed diagnosis of relapsed or refractory lymphoma who have received at least two prior lines of therapy including immuno-chemotherapy. Patients with relapsed chronic lymphoid leukemia (CLL) are eligible if they have received one or more prior lines of any approved standard therapy.
- Detailed eligibility reviewed when you contact the study team.
Study Summary
This clinical trial is for men and women with relapsed or refractory lymphoma. Despite conventional therapies, such as chemotherapy and radiation therapy, the treatment of lymphomas remains challenging, with the disease relapsing in many patients, which is subsequently more difficult to treat. The main goal of this study is to investigate the efficacy of PQR309 in patients with relapsed or refractory lymphomas. This is an open-label, non-randomized, multicenter phase 2 study with a safety run-in evaluating efficacy and safety of PQR309 in patients with relapsed or refractory lymphoma. There will be a safety run-in phase with up to 12 patients treated with 60 or 80 milligrams every day and then a Phase 2 expansion phase conducted with the highest dose level considered to be safe. Patients will take 60 mg or 80 mg PQR309 orally once daily and will continue treatment as long as they are responding to therapy and not experiencing unacceptable side effects.
New Developments in Lymphoma 